Results 151 to 160 of about 2,144,368 (379)
Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence
Gabriel E. Neurohr +18 more
semanticscholar +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source
Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller +17 more
wiley +1 more source
Early and late selection: Effects of load, dilution and salience
Tal eMakovski +2 more
doaj +1 more source
Perspectives on dilution jet mixing [PDF]
A microcomputer code which displays 3-D oblique and 2-D plots of the temperature distribution downstream of jets mixing with a confined crossflow has been used to investigate the effects of varying the several independent flow and geometric parameters on
Holdeman, J. D.
core +1 more source
Optimal design of dilution experiments under volume constraints [PDF]
The paper develops methods to construct a one-stage optimal design of dilution experiments under the total available volume constraint typical for bio-medical applications.
Zolghadr, Maryam, Zuyev, Sergei
core
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad +35 more
wiley +1 more source

